Close

Bristol-Myers Squibb (BMY), Infinity Pharma (INFI) Enter Advanced Solid Tumors-Focused Collaboration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. CMG


Go back to Bristol-Myers Squibb (BMY), Infinity Pharma (INFI) Enter Advanced Solid Tumors-Focused Collaboration

Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors

November 9, 2016 6:59 AM EST

Evaluation of IPI-549 as a monotherapy continuing, with combination portion of Phase 1 study expected to begin this fall Study to evaluate potential of IPI-549 plus Opdivo to target immune-suppressive cells in the tumor microenvironment

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and... More